NASDAQ:HUMA Humacyte - HUMA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.24 +0.33 (+11.34%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.94▼$3.3350-Day Range$2.49▼$3.2552-Week Range$1.96▼$8.04Volume206,835 shsAverage Volume253,120 shsMarket Capitalization$334.11 millionP/E RatioN/ADividend YieldN/APrice Target$5.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Humacyte MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside152.7% Upside$8.19 Price TargetShort InterestBearish9.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.96) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 starsMedical Sector802nd out of 995 stocksBiological Products, Except Diagnostic Industry139th out of 166 stocks 3.2 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.19, Humacyte has a forecasted upside of 152.7% from its current price of $3.24.Amount of Analyst CoverageHumacyte has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.44% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.Change versus previous monthShort interest in Humacyte has recently increased by 2.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 1.9 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Humacyte this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have not sold or bought any company stock.Percentage Held by Insiders25.00% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.05% of the stock of Humacyte is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($0.96) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -24.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -24.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Humacyte (NASDAQ:HUMA) StockHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comHumacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business UpdateMarch 21, 2023 | finance.yahoo.comHumacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023March 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 7, 2023 | msn.comZymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat EstimatesFebruary 13, 2023 | sg.finance.yahoo.comHumacyte, Inc. (HUMA)February 10, 2023 | marketwatch.comBioprosthetics Market 2023 [New Report]: Qualitative Insights by Massive Growth and Share Forecast to 2028January 30, 2023 | seekingalpha.comHumacyte: With 2 BLAs Ahead, Solid Cash, Current Lows Make It UndervaluedJanuary 24, 2023 | finance.yahoo.comHumacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery DiseaseMarch 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. January 15, 2023 | finance.yahoo.comHumacyte, Inc. (HUMA) Stock Historical Prices & Data - Yahoo FinanceDecember 13, 2022 | finance.yahoo.comHumacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in WartimeDecember 1, 2022 | finance.yahoo.comHumacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022November 23, 2022 | finance.yahoo.comHumacyte to Present at the 34th Annual Piper Sandler Healthcare ConferenceNovember 10, 2022 | finance.yahoo.comHumacyte Third Quarter 2022 Financial Results and Business UpdateNovember 7, 2022 | finance.yahoo.comHumacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 MeetingNovember 3, 2022 | finance.yahoo.comHumacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022October 13, 2022 | seekingalpha.comHumacyte: Intriguing Potential (NASDAQ:HUMA) - Seeking AlphaOctober 9, 2022 | fool.comHumacyte, Inc. (NASDAQ: HUMA)September 23, 2022 | globenewswire.comHumacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting - GlobeNewswireSeptember 23, 2022 | finance.yahoo.comHumacyte, Inc.'s (NASDAQ:HUMA) last week's 12% decline must have disappointed individual investors who have a significant stake - Yahoo FinanceSeptember 23, 2022 | bizjournals.com2022 CEO of the Year & C-suite Awards: Laura Niklason – Humacyte - The Business JournalsSeptember 23, 2022 | finance.yahoo.comHumacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual MeetingSeptember 20, 2022 | finance.yahoo.comHumacyte Expands Board of Directors and Leadership Team with New Appointments - Yahoo FinanceSeptember 20, 2022 | globenewswire.comHumacyte Expands Board of Directors and Leadership Team with New Appointments - GlobeNewswireSeptember 20, 2022 | finance.yahoo.comHumacyte Expands Board of Directors and Leadership Team with New AppointmentsSeptember 9, 2022 | finance.yahoo.comHumacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress - Yahoo FinanceSeptember 9, 2022 | streetinsider.comForm N-CSRS Listed Funds Trust For: Jun 30 - StreetInsider.comSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Company Calendar Today3/28/2023Next Earnings (Estimated)5/12/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.19 High Stock Price Forecast$16.00 Low Stock Price Forecast$2.75 Forecasted Upside/Downside+72.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins1,971.30% Pretax Margin1,970.90% Return on Equity-74.59% Return on Assets-35.49% Debt Debt-to-Equity Ratio0.37 Current Ratio9.75 Quick Ratio9.75 Sales & Book Value Annual Sales$1.26 million Price / Sales265.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book2.72Miscellaneous Outstanding Shares103,120,000Free Float77,339,000Market Cap$334.11 million OptionableOptionable Beta1.22 Key ExecutivesDr. Laura E. Niklason M.D. (Age 59)Ph.D., Founder, Pres, CEO & Director Comp: $783.36kMr. Dale A. Sander (Age 62)CFO, Chief Corp. Devel. Officer & Treasurer Comp: $12.5kDr. Heather Ledbetter Prichard Ph.D. (Age 44)Chief Operating Officer Comp: $576.44kDr. Juliana L. Blum Ph.D.Co-Founder & Exec. VP of Corp. Devel.Ms. Sabrina OsborneExec. VP of Bus. Strategy & PeopleMr. William John Scheessele (Age 50)Chief Commercial Officer Dr. Shamik J. Parikh M.D. (Age 49)Chief Medical Officer Mr. Harold AltersonSr. VP of QualityDr. Yang Cao M.D.Ph.D., Chief Regulatory OfficerMore ExecutivesKey CompetitorsDBV TechnologiesNASDAQ:DBVTVoyager TherapeuticsNASDAQ:VYGRTarsus PharmaceuticalsNASDAQ:TARSAutolus TherapeuticsNASDAQ:AUTLPoseida TherapeuticsNASDAQ:PSTXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 34,928 shares on 3/23/2023Ownership: 0.034%Voya Investment Management LLCBought 21,174 shares on 2/28/2023Ownership: 0.021%Kovack Advisors Inc.Bought 25,000 shares on 2/22/2023Ownership: 0.024%Alliancebernstein L.P.Bought 15,500 shares on 2/16/2023Ownership: 0.015%State of Wisconsin Investment BoardSold 3,545 shares on 2/15/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions HUMA Stock - Frequently Asked Questions Should I buy or sell Humacyte stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HUMA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUMA, but not buy additional shares or sell existing shares. View HUMA analyst ratings or view top-rated stocks. What is Humacyte's stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month price targets for Humacyte's stock. Their HUMA share price forecasts range from $2.75 to $16.00. On average, they anticipate the company's share price to reach $8.19 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts. How have HUMA shares performed in 2023? Humacyte's stock was trading at $2.11 at the beginning of the year. Since then, HUMA stock has increased by 53.6% and is now trading at $3.24. View the best growth stocks for 2023 here. When is Humacyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023. View our HUMA earnings forecast. What ETFs hold Humacyte's stock? ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Changebridge Capital Long/Short Equity ETF (CBLS).Changebridge Capital Sustainable Equity ETF (CBSE). What is Humacyte's stock symbol? Humacyte trades on the NASDAQ under the ticker symbol "HUMA." Who are Humacyte's major shareholders? Humacyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.85%), Charles Schwab Investment Management Inc. (0.39%), LPL Financial LLC (0.28%), Bank of America Corp DE (0.11%), Credit Suisse AG (0.06%) and State of Wisconsin Investment Board (0.05%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Laura E Niklason, Michael T Constantino and William John Scheessele. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Humacyte's stock price today? One share of HUMA stock can currently be purchased for approximately $3.24. How much money does Humacyte make? Humacyte (NASDAQ:HUMA) has a market capitalization of $334.11 million and generates $1.26 million in revenue each year. The company earns $-26,480,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis. How many employees does Humacyte have? The company employs 145 workers across the globe. How can I contact Humacyte? Humacyte's mailing address is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. The official website for the company is www.constellationalpha.com. The company can be reached via phone at 919-313-9633 or via email at investors@humacyte.com. This page (NASDAQ:HUMA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.